ASMB

Assembly Biosciences Inc

Apr 02 • 04:00PM ET

29.01

-0.42 -1.43 %

Healthcare • Biotechnology • USA • NASD

Peers: GILD ABUS IONS ENTA MDGL NBIX VKTX ADAP OMER LXRX

Index	-	P/E	-	EPS (ttm)	-1.84	Insider Own	33.69%	Shs Outstand	15.86M	Perf Week	0.48%
Market Cap	460.18M	Forward P/E	-	EPS next Y	-3.01	Insider Trans	-0.01%	Shs Float	10.52M	Perf Month	-2.62%
Enterprise Value	214.70M	PEG	-	EPS next Q	-0.65	Inst Own	56.88%	Short Float	14.46%	Perf Quarter	-14.70%
Income	-6.12M	P/S	6.36	EPS this Y	-256.36%	Inst Trans	10.94%	Short Ratio	15.67	Perf Half Y	17.88%
Sales	72.30M	P/B	2.22	EPS next Y	-53.57%	ROA	-3.24%	Short Interest	1.52M	Perf YTD	-14.70%
Book/sh	13.04	P/C	1.85	EPS next 5Y	-	ROE	-5.10%	52W High	39.71 -26.94%	Perf Year	206.34%
Cash/sh	15.64	P/FCF	-	EPS past 3/5Y	71.29% 51.83%	ROIC	-2.93%	52W Low	7.75 274.32%	Perf 3Y	187.66%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -1.78%	Gross Margin	99.82%	Volatility	6.04% 5.36%	Perf 5Y	-46.98%
Dividend TTM	-	EV/Sales	2.97	EPS Y/Y TTM	72.62%	Oper. Margin	-16.76%	ATR (14)	1.61	Perf 10Y	-53.60%
Dividend Ex-Date	-	Quick Ratio	5.22	Sales Y/Y TTM	153.52%	Profit Margin	-8.47%	RSI (14)	52.91	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	5.22	EPS Q/Q	188.72%	SMA20	2.10%	Beta	1.21	Target Price	48.75
Payout	-	Debt/Eq	0.01	Sales Q/Q	477.26%	SMA50	3.60%	Rel Volume	0.39	Prev Close	29.43
Employees	73	LT Debt/Eq	0.01	Earnings	Mar 19 AMC	SMA200	7.05%	Avg Volume	97.04K	Price	29.01
IPO	Dec 17, 2010	Option/Short	Yes / Yes	EPS/Sales Surpr.	262.69% 472.25%	Trades		Volume	37,857	Change	-1.43%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-24-25	Initiated	Citizens JMP	Mkt Outperform	$38
Aug-18-25	Resumed	H.C. Wainwright	Buy	$50
Mar-25-25	Initiated	Guggenheim	Buy	$31
Sep-20-24	Upgrade	Jefferies	Hold → Buy	$2 → $35
Sep-13-21	Initiated	H.C. Wainwright	Neutral	$3.50
Sep-02-21	Downgrade	William Blair	Outperform → Mkt Perform
Mar-23-21	Downgrade	SVB Leerink	Outperform → Mkt Perform
Nov-06-20	Downgrade	Jefferies	Buy → Hold	$30 → $10
Oct-19-20	Initiated	Truist	Buy	$55
Oct-16-19	Initiated	Mizuho	Buy	$20
Nov-19-18	Initiated	Leerink Partners	Outperform	$45
Oct-08-18	Upgrade	B. Riley FBR	Neutral → Buy	$42
Aug-08-18	Initiated	Robert W. Baird	Outperform	$74
Apr-13-18	Downgrade	Chardan Capital Markets	Buy → Neutral	$35 → $50
Jan-05-18	Initiated	B. Riley FBR, Inc.	Neutral	$35
Nov-08-17	Initiated	Jefferies	Buy	$50
May-30-17	Initiated	Chardan Capital Markets	Buy	$35

Show Previous Ratings

Mar-19-26 04:26PM	Assembly Biosciences: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Assembly Biosciences Reports Year-End 2025 Financial Results and Recent Highlights (GlobeNewswire)
Mar-05-26 05:30PM	Metagenomi Therapeutics (MGX) Reports Q4 Loss, Misses Revenue Estimates (Zacks) -7.15%
Feb-26-26 05:30PM	Personalis (PSNL) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
Feb-24-26 09:55PM	Supernus Pharmaceuticals (SUPN) Surpasses Q4 Earnings and Revenue Estimates (Zacks)
10:45AM	Loading…
Dec-23-25 10:45AM	GILD Exercises Option to License Assembly Bio's Herpes Programs (Zacks) -9.54%
Dec-22-25 08:00AM	Gilead Sciences Exercises Option to License Assembly Biosciences' Helicase-Primase Inhibitor Programs for Recurrent Genital Herpes (Business Wire)
Dec-08-25 04:05PM	Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Studies of Long-Acting Helicase-Primase Inhibitor Candidates ABI-1179 and ABI-5366 Showing Reductions in Viral Shedding Rate and Virologically Confirmed Genital Lesion Rate in Recurrent Genital Herpes (GlobeNewswire)
Nov-10-25 04:18PM	Assembly Biosciences: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Assembly Biosciences Reports Third Quarter 2025 Financial Results and Recent Updates (GlobeNewswire)
Nov-07-25 08:00AM	Assembly Biosciences Presents Positive Phase 1b Data for Next-Generation Capsid Assembly Modulator ABI-4334 at AASLD The Liver Meeting (GlobeNewswire)
Nov-04-25 05:20PM	Supernus Pharmaceuticals (SUPN) Surpasses Q3 Earnings and Revenue Estimates (Zacks)
Oct-29-25 11:57AM	H.C. Wainwright Reaffirms Buy Rating on Assembly Biosciences, Inc. (ASMB) Amid Promising Trial Data (Insider Monkey)
Oct-14-25 07:00AM	Assembly Biosciences Announces Upcoming Investor Conference Participation (GlobeNewswire)
Oct-10-25 08:00AM	Assembly Biosciences Presents Interim Phase 1b Data for HSV Helicase-Primase Inhibitor Candidate ABI-5366 at the 38th Congress of the International Union Against Sexually Transmitted Infections (IUSTI)- Europe (GlobeNewswire)
09:40AM	Loading…
Sep-25-25 09:40AM	Amazon upgraded, Adobe downgraded: Wall Streets top analyst calls (TipRanks)
Sep-24-25 09:36AM	Amazon upgraded, Adobe downgraded: Wall Street's top analyst calls (The Fly)
Sep-22-25 10:32AM	Assembly Biosciences (ASMB) Surges 9.8%: Is This an Indication of Further Gains? (Zacks)
Aug-11-25 07:26AM	Assembly Bios herpes drug shows 94% drop in viral shedding (Clinical Trials Arena)
Aug-08-25 08:05AM	Assembly Biosciences Announces Pricing of $175 Million in Equity Financings (GlobeNewswire) +12.96%
08:00AM	Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Study of Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366 Showing Reductions in Viral Shedding Rate and Genital Lesion Rate in Recurrent Genital Herpes (GlobeNewswire)
Aug-06-25 05:20PM	Assembly Biosciences: Q2 Earnings Snapshot (Associated Press Finance) +9.21%
04:05PM	Assembly Biosciences Reports Second Quarter 2025 Financial Results and Recent Updates (GlobeNewswire)
04:05PM	Assembly Biosciences Reports Interim Phase 1a Data from Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus (GlobeNewswire)
Jul-26-25 03:00AM	Assembly Biosciences Presents Data Highlighting Recurrent Genital Herpes Program at STI & HIV 2025 World Congress and International Herpesvirus Workshop (GlobeNewswire)
Jul-24-25 11:48PM	Assembly Bio's (ASMB) HBV Drug Shows Strong Efficacy in Phase 1b Trial (Insider Monkey)
Jul-02-25 10:09PM	Assembly Biosciences, Inc. (ASMB) Announces Key Leadership and Plan Changes (Insider Monkey)
Jul-01-25 10:50AM	First subject dosed in Assembly Biosciences study for genital herpes (Clinical Trials Arena)
Jun-30-25 08:00AM	Assembly Biosciences Doses First Participant in Phase 1b Portion of Phase 1a/b Clinical Trial of Investigational Long-Acting Herpes Simplex Virus Helicase-Primase Inhibitor ABI-1179 (GlobeNewswire)
Jun-25-25 08:00AM	Assembly Biosciences Reports Positive Topline Results from Phase 1b Clinical Trial of Next-Generation Investigational Capsid Assembly Modulator ABI-4334 in Chronic Hepatitis B (GlobeNewswire)
04:05PM	Loading…
May-27-25 04:05PM	Assembly Biosciences to Present During the Jefferies 2025 Global Healthcare Conference (GlobeNewswire)
May-08-25 05:40PM	Assembly Biosciences (ASMB) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -6.04%
04:36PM	Assembly Biosciences: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Assembly Biosciences Reports First Quarter 2025 Financial Results and Recent Updates (GlobeNewswire)
May-07-25 05:35PM	Amphastar Pharmaceuticals (AMPH) Tops Q1 Earnings Estimates (Zacks)
08:00AM	New Preclinical Data for Assembly Biosciences' Oral Hepatitis D Virus Entry Inhibitor ABI-6250 and Next-Generation Hepatitis B Virus Capsid Assembly Modulator ABI-4334 Presented at the EASL Congress 2025 (GlobeNewswire)
May-05-25 09:47AM	Assembly Biosciences (ASMB) Soars 24.0%: Is Further Upside Left in the Stock? (Zacks)
Apr-29-25 05:35PM	BridgeBio Pharma (BBIO) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +6.38%
Apr-09-25 02:00AM	Assembly Biosciences Presents New Data Highlighting Long-Acting Herpes Simplex Virus Candidate ABI-5366 and Genital Herpes Prevalence and Treatment Patterns at the 2025 ESCMID Congress (GlobeNewswire)
Apr-08-25 09:35AM	Down -22.6% in 4 Weeks, Here's Why Assembly Biosciences (ASMB) Looks Ripe for a Turnaround (Zacks)
Mar-26-25 12:00PM	Assembly Biosciences (ASMB) Upgraded to Buy: What Does It Mean for the Stock? (Zacks) -5.34%
Mar-20-25 04:53PM	Assembly Biosciences files for $250 mixed securities shelf (SeekingAlpha)
04:05PM	Assembly Biosciences Reports Year End 2024 Financial Results and Recent Highlights (GlobeNewswire)
Mar-04-25 08:34PM	Is Assembly Biosciences, Inc. (ASMB) Among Stocks With At Least $20 Million In Insider Spending Recently? (Insider Monkey)
Feb-26-25 08:00AM	Assembly Biosciences Doses First Participant in Phase 1a Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus (GlobeNewswire) +7.86%
Feb-20-25 08:00AM	Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor ABI-1179 in Development for Recurrent Genital Herpes (GlobeNewswire)
Dec-29-24 03:00AM	Gilead Buys $20.1 Million of Assembly Biosciences Stock (Barrons.com)
Dec-26-24 08:00AM	Assembly Biosciences Reports Interim Phase 1b Results from Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 in Chronic Hepatitis B (GlobeNewswire)
Dec-19-24 08:00AM	Assembly Biosciences Announces $30.1 Million Equity Investment and Accelerated Funding from Gilead to Advance Clinical Development Programs (GlobeNewswire) +17.02%
Nov-07-24 06:19PM	Assembly Biosciences: Q3 Earnings Snapshot (Associated Press Finance) +5.11%
04:05PM	Assembly Biosciences Reports Third Quarter 2024 Financial Results and Recent Updates (GlobeNewswire)
Sep-23-24 01:39PM	Assembly Biosciences' Investigational Herpes Treatment Shows Safety In Healthy Participants (UPDATED) (Benzinga) -16.31%
08:00AM	Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366 (GlobeNewswire)
Sep-16-24 09:40AM	Is Assembly Biosciences (ASMB) Stock Outpacing Its Medical Peers This Year? (Zacks)
Aug-08-24 05:22PM	Assembly Biosciences: Q2 Earnings Snapshot (Associated Press Finance) +6.02%
04:05PM	Assembly Biosciences Reports Second Quarter 2024 Financial Results and Recent Updates (GlobeNewswire)
Jul-15-24 08:00AM	Assembly Biosciences Presents New Preclinical Data Highlighting Investigational Helicase-Primase Inhibitors at International Herpesvirus Workshop (GlobeNewswire)
Jun-18-24 08:00AM	Assembly Biosciences Doses First Participant in Phase 1b Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 for the Treatment of Chronic Hepatitis B Virus Infection (GlobeNewswire)
Jun-17-24 08:00AM	Assembly Biosciences Announces $12.6 Million in Equity Financings (GlobeNewswire)
Jun-10-24 08:00AM	Assembly Biosciences Doses First Participant in Phase 1a/b Clinical Trial of Herpes Simplex Virus Helicase-Primase Inhibitor Candidate ABI-5366 (GlobeNewswire) +6.51%
Jun-05-24 08:00AM	Assembly Biosciences Presents New Data Highlighting Hepatitis D Virus Entry Inhibitor ABI-6250 at the EASL Congress 2024 (GlobeNewswire)
May-22-24 08:00AM	Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL Congress 2024 (GlobeNewswire)
May-13-24 08:53AM	ASMB Stock Earnings: Assembly Biosciences Beats EPS for Q1 2024 (InvestorPlace)
May-09-24 05:04AM	Assembly Biosciences: Q1 Earnings Snapshot (Associated Press Finance)
May-08-24 04:05PM	Assembly Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights (GlobeNewswire)
Mar-28-24 10:53PM	ASMB Stock Earnings: Assembly Biosciences Beats EPS for Q4 2023 (InvestorPlace)
04:05PM	Assembly Biosciences Reports Fourth Quarter and Year End 2023 Financial Results and Recent Highlights (GlobeNewswire)
Mar-25-24 12:52PM	ASMB Stock Earnings: Assembly Biosciences Misses EPS for Q2 2023 (InvestorPlace)
Feb-08-24 08:00AM	Assembly Biosciences Announces Effective Date of Reverse Stock Split (GlobeNewswire)
Jan-04-24 08:00AM	Assembly Biosciences Provides Anticipated Development Milestones for 2024 (GlobeNewswire)
Nov-10-23 04:05PM	Assembly Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.11%
08:00AM	Assembly Biosciences Presents New Data Highlighting Viral Hepatitis Portfolio at AASLD The Liver Meeting (GlobeNewswire)
Nov-08-23 05:08PM	Assembly Biosciences: Q3 Earnings Snapshot (Associated Press Finance) -12.48%
04:05PM	Assembly Biosciences Reports Third Quarter 2023 Financial Results and Recent Updates (GlobeNewswire)
08:00AM	Assembly Biosciences Names Anuj Gaggar, MD, PhD, as Chief Medical Officer (GlobeNewswire)
Oct-17-23 10:59AM	Why Is Assembly Biosciences (ASMB) Stock Up 92% Today? (InvestorPlace) +72.18%
07:00AM	Gilead and Assembly Biosciences Establish Partnership to Develop Next-Generation Therapeutics for Serious Viral Diseases (Business Wire)
Oct-11-23 08:00AM	Assembly Biosciences to Present New Data at AASLD The Liver Meeting (GlobeNewswire)
Oct-02-23 08:00AM	Assembly Biosciences Nominates Development Candidate ABI-6250, an Orally Bioavailable HDV Entry Inhibitor (GlobeNewswire)
Sep-19-23 04:05PM	Assembly Biosciences to Highlight Pipeline Progress in HBV and HDV at the 2023 International HBV Meeting (GlobeNewswire) -5.72%
Aug-09-23 06:11PM	Assembly Biosciences: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Assembly Biosciences Reports Second Quarter 2023 Financial Results and Recent Updates (GlobeNewswire)
Jul-17-23 08:00AM	Assembly Biosciences Presents New Data Highlighting Herpes Simplex Virus Development Candidate ABI-5366 at the 47th Annual International Herpesvirus Workshop (GlobeNewswire)
Jun-21-23 08:00AM	Assembly Biosciences Presents New Data Highlighting Entry Inhibitor and Core Inhibitor Programs at EASLs International Liver Congress 2023 (GlobeNewswire)
Jun-07-23 08:00AM	Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL International Liver Congress 2023 (GlobeNewswire)
May-23-23 04:05PM	Assembly Biosciences to Present During the 2023 Jefferies Healthcare Conference (GlobeNewswire)
May-04-23 06:28PM	Assembly Biosciences: Q1 Earnings Snapshot (AP Finance)
04:05PM	Assembly Biosciences Reports First Quarter 2023 Financial Results and Recent Highlights (GlobeNewswire)
Apr-18-23 08:00AM	Assembly Biosciences Announces Additional Promising Data from Phase 1a Clinical Trial Evaluating Highly Potent Next-Generation Core Inhibitor Candidate ABI-4334 and Provides Pipeline Update (GlobeNewswire)
Mar-30-23 10:04AM	Companies Like Assembly Biosciences (NASDAQ:ASMB) Could Be Quite Risky (Simply Wall St.) -10.11%
Mar-22-23 04:05PM	Assembly Biosciences Provides Update on its Core Inhibitor Pipeline, Reports Fourth Quarter and Year End 2022 Financial Results and Recent Highlights (GlobeNewswire) -8.55%
Feb-15-23 08:00AM	Assembly Biosciences Nominates First Herpesvirus Development Candidate ABI-5366, a Long-Acting HSV-2 Helicase Inhibitor Targeting High-Recurrence Genital Herpes (GlobeNewswire)
Dec-19-22 03:19PM	Assembly Biosciences Shares Gain After Promising Early Cut Data From HBV Infection Programs (Benzinga) +14.53%
08:00AM	Assembly Biosciences Announces Promising Interim Results from Two Clinical Trials Evaluating Highly Potent Next-Generation Core Inhibitor Candidates ABI-H3733 and ABI-4334 (GlobeNewswire)
Nov-14-22 08:00AM	Assembly Biosciences Doses First Subject in Phase 1a Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetic Profile of Investigational Next Generation Core Inhibitor ABI-4334 (GlobeNewswire) +8.21%
Nov-09-22 09:35AM	After Plunging 17% in 4 Weeks, Here's Why the Trend Might Reverse for Assembly Biosciences (ASMB) (Zacks)
Nov-08-22 04:05PM	Assembly Biosciences Reports Third Quarter 2022 Financial Results and Recent Highlights and Announces Upcoming Conference Participation (GlobeNewswire) -7.43%
Nov-04-22 08:00AM	Assembly Biosciences Presents New Data at AASLD The Liver Meeting® Highlighting Breadth of Virology Portfolio and Potential of Next-Generation Core Inhibitors in HBV (GlobeNewswire) -5.00%
Oct-24-22 08:00AM	Assembly Biosciences to Present Data in Four Poster Presentations at Upcoming AASLD The Liver Meeting® (GlobeNewswire)
Oct-21-22 09:36AM	Can Assembly Biosciences (NASDAQ:ASMB) Afford To Invest In Growth? (Simply Wall St.)

Assembly Biosciences, Inc. is a biotechnology company that focuses on developing small molecule antiviral therapeutics for serious viral diseases. Its lead programs, ABI-5366 and ABI-1179, long-acting helicase-primase inhibitors, are in clinical development for recurrent genital herpes. The company is partnered with Gilead Sciences to advance current and future antiviral programs across herpesviruses, HBV, and HDV. Assembly Biosciences was founded in 2005 and is headquartered in South San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Bjorkquist Jeanette M	PFO and PAO	Mar 30 '26	Sale	26.69	328	8,755	11,089	Mar 31 04:25 PM
White Nicole S	Chief Manufacturing Officer	Mar 30 '26	Sale	26.69	197	5,258	37,477	Mar 31 04:20 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ASMB

Assembly Biosciences Inc

Upgrade your Finviz experience